
Opinion: Stop blaming Biogen for putting profit at the expense of patients. Blame the systems that enabled it
Two congressional committees recently released damning results of an 18-month investigation into the Food and Drug Administration’s approval of Biogen’s controversial Alzheimer’s drug, Aduhelm. The systems that enabled Biogen’s actions, …
Read More